Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Ranibizumab Stories

2013-09-09 08:26:48

INCLINE VILLAGE, Nev., Sept. 9, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2013, of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) The forecasted growth in revenues is driven by increased second quarter 2013 sales for Avastin(®),...

2013-08-15 08:26:16

Eylea's Convenient Dosing Frequency Likely Drives Product Initiation, Although High Satisfaction Among Prescribers Likely Motivates Continued Use, According to a New Report from BioTrends Research Group EXTON, Penn., Aug. 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed retinal specialists/general ophthalmologists now treat 26 percent of their intravitreal...

2013-08-07 08:30:31

CereKin(TM) (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis. SAN FRANCISCO, Aug. 7, 2013 /PRNewswire/ -- Kindred Biosciences, Inc. (Kindred Bio) announced today that it has initiated a pivotal clinical trial for CereKin(TM) (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of...

2013-07-19 15:30:13

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose. The results of a two-year trial, led by Queen's scientist Professor Usha Chakravarthy, and published in The Lancet today (Friday 19 July), show that two drug treatments Lucentis and Avastin are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD). Wet AMD is...

2013-07-10 08:28:42

Regardless of First-Line Therapy Choice, Treatment Typically Occurs Within Same Month As Wet AMD Diagnosis, According to a New Report from BioTrends Research Group EXTON, Pa., July 10, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal anti-vascular endothelial...

Promising Results From Pilot Study For AMD
2013-06-18 13:40:01

University of Iowa There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, “wet” stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two...

2013-06-18 08:30:37

VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME).  The study has shown a good safety profile with no drug-related serious adverse events to date. "The last patient was enrolled and treated on June 17," said Andrew Rae, President &...

2013-06-05 11:53:36

Manufacturer's dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the...

2013-05-29 08:28:06

Lucentis's Prescriber Base and Patient Share Have Grown But Cost-Related Obstacles Remain, According to a New Report from BioTrends Research Group EXTON, Pa., May 29, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, despite the approval of Genentech's Lucentis 0.3 mg in August 2012 as the first intravitreal therapy (IVT) for the treatment of diabetic macular edema (DME),...

2013-03-11 08:26:59

INCLINE VILLAGE, Nev., March 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2013, of approximately $92 million, as compared with actual royalty revenue of $77 million for the first quarter of 2012, a 19 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) The forecasted growth in royalty revenues is driven by increased fourth quarter 2012 sales for all licensed...